Alvotech Eyes $450m Funding And Public Listing With SPAC Merger

Proposed Combination Would Have Initial Enterprise Value Of Around $2.25bn

 
• By Dean Rudge
  
Nasdaq 2021
Alvotech's shares would trade on the Nasdaq • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business